---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-010211"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:35:12.872123+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025

## Summary
- Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.
- Cash and investments $90.1M at Dec 31, 2024, down $81.7M from year-end 2023; $42.7M cost outlays.
- OMIDRIA royalties Q4 $10.1M on Rayner sales $33.6M, up from $9.3M on $31.0M in Q3.
- BLA for narsoplimab in TA-TMA resubmitted to FDA Mar 2025; PDUFA target September 2025.
- Phase 3 for zaltenibart in PNH initiated; NIDA awarded $4.02M for OMS527 CUD study; data readout by year-end 2025.

## SEC filing metadata
- accession: 0001437749-25-010211
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/0001437749-25-010211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/omer20241119_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-010211
- JSON: https://secwatch.observer/filing/0001437749-25-010211.json
- Plain text: https://secwatch.observer/filing/0001437749-25-010211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.